Drug firm Lupin on Friday said the inspection of its three units at Pithampur inMadhya Pradeshby the UK health regulator has been successfully completed.
The inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK at the company's three manufacturing units in Pithampur has been closed, Lupin saidin a statement.
The inspection was conducted in January 2020, it added.
We are committed to maintaining truly global quality standards at all our manufacturing facilities. The successful close out of the inspection at Pithampur, and release of the inspection report by UK MHRA further bolsters our confidence in our quality standards and manufacturing processes, Lupin MD Nilesh Gupta said.
Shares of Lupin settled at Rs835.20per scrip on the BSE, up2.65 per cent, from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
